Fresh Tracks Therapeutics Azioni (OTC: FRTX)

Ultime notizie per Fresh Tracks Therapeutics (OTC:FRTX) Azioni

Fresh Tracks Therapeutics

Fresh Tracks Therapeutics Inc does not have any operations as it has discontinued its activities.

FRESH TRACKS THERAPEUTICS by Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics Inc

News

Guidance

BILL

BILL Holding Sees FY25 Adj. EPS $1.65-$1.83 Vs $1.55 Est.; $1.439B-$1.464B Vs $1.437B

Research Frontiers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) reported $354.41 thousand in sales this quarter. This is a 115.91 percent increase over sales of $164.15 thousand the same period last year.

Earnings

REFR

Research Frontiers Q3 Sales $354.41K Up From $164.15K YoY

BILL Holding Sees Q2 Adj. EPS $0.44-$0.48; Revenue $355.5M-$360.5M

ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.14 by 142.86 percent. The company reported quarterly sales of $285.25 million which missed the analyst consensus estimate of $316.34 million by 9.83 percent. This is a 17.67 percent increase over sales of $242.42 million the same period last year.

Earnings Beats

Earnings Misses

ProAssurance Q3 2024 Adj EPS $0.34 Beats $0.14 Estimate, Sales $285.25M Miss $316.34M Estimate

Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) affirms FY2024 sales outlook from $410.00 million-425.00 million to $410.00 million-425.00 million.

BRLT

Brilliant Earth Group Affirms FY2024 Sales Guidance from $410.00M-425.00M to $410.00M-425.00M

Mettler-Toledo Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) reported quarterly earnings of $10.21 per share which beat the analyst consensus estimate of $10.01 by 2 percent. The company reported quarterly sales of $954.53 million which beat the analyst consensus estimate of $944.74 million by 1.04 percent. This is a 1.28 percent increase over sales of $942.46 million the same period last year.

Mettler-Toledo Intl Q3 2024 Adj EPS $10.21 Beats $10.01 Estimate, Sales $954.53M Beat $944.74M Estimate

Consensus Cloud Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) affirms FY2024 Adj EPS guidance from $5.45-5.55 to $5.45-5.55 vs $5.50 analyst estimate. Narrows FY2024 sales outlook from $338.00 million-353.00 million to $346.00 million-350.00 million vs $344.10 million estimate.

CCSI

Consensus Cloud Solns Affirms FY2024 Adj EPS Guidance from $5.45-5.55 to $5.45-5.55 vs $5.50 Est; Narrows FY2024 Sales Guidance from $338.00M-353.00M to $346.00M-350.00M vs $344.10M Est

Outlook2
For the fourth quarter ending December 31, 2024, Toast expects to report:
<ul>
<li>Non-GAAP subscription services and financial technology solutions gross profit in the range of $370 million to $380 million (32-35% growth compared to Q4 2023)</li>
<li>Adjusted EBITDA in the range of $90 million to $100 million</li>
</ul>
For the full year ending December 31, 2024, Toast expects to report:
<ul>
<li>Non-GAAP subscription services and financial technology solutions gross profit in the range of $1,395 million to $1,405 million (32-33% growth compared to 2023, up from 27-29% growth)</li>
<li>Adjusted EBITDA in the range of $352 million to $362 million (up from $285 million to $305 million)</li>
</ul>
The outlook provided above constitutes forward-looking information within the meaning of applicable securities laws and is based on a number of assumptions and subject to a number of risks. See cautionary note regarding "Forward-looking Statements" in this press release.

TOST

Toast Sees Q4 Non-GAAP Subscription Services And Financial Technology Solutions Gross Profit In The Range Of $370M-$380M; FY24 Non-GAAP Subscription Services And Financial Technology Solutions Gross Profit In The Range Of $1.395B-$1.405B

Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent.

ALLO

Allogene Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate

Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.06 by 33.33 percent. This is a 20 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $286.87 million which beat the analyst consensus estimate of $282.56 million by 1.52 percent. This is a 4.16 percent increase over sales of $275.40 million the same period last year.

GTBIF

Green Thumb Industries Q3 EPS $0.04 Misses $0.06 Estimate, Sales $286.87M Beat $282.56M Estimate

NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) lowers FY2024 Adj EPS guidance from $5.13-5.20 to $1.15-1.19 vs $1.29 analyst estimate. Lowers FY2024 sales outlook from $944.00 million-950.00 million to $939.00 million-943.00 million vs $946.02 million estimate.

NVEE

NV5 Global provides FY2024 guidance: Gross revenues $939M-$943M (est. 946.02M); GAAP EPS $0.48-$0.54 (est. 0.67); Adj. EPS $1.15-$1.19 (adjusted for 4-1 stock split) vs (est. 1.29)

Consensus Cloud Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) is looking for Q4 Adj EPS of $1.14-1.24 vs $1.21 analyst estimate. sees sales of $83.000 million-87.000 million vs $83.26 million estimate.

Consensus Cloud Solns Sees Q4 Adj EPS $1.14-1.24 vs $1.21 Est; Sees Sales $83.000M-87.000M vs $83.26M Est

SENS

Senseonics Sees FY24 Revenue $22M Vs $22.182M Est.

DXC Technology Sees Q3 2025 Revenue $3.2B-$3.3B Vs $3.2B Est.; Sees Adj EPS $0.75-$0.80 Vs $0.72 Est.

Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $1.965 million which missed the analyst consensus estimate of $5.420 million by 63.74 percent. This is a 56.60 percent decrease over sales of $4.528 million the same period last year.

GEVO

Gevo Q3 2024 GAAP EPS $(0.09) Misses $(0.07) Estimate, Sales $1.965M Miss $5.420M Estimate

SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) reported quarterly earnings of $0.02 per share. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported $10.00 million in sales this quarter. This is a 8.28 percent increase over sales of $9.23 million the same period last year.

SIGA

SIGA Technologies Q3 EPS $0.02 Up From $(0.01) YoY, Sales $10.00M Up From $9.23M YoY

PODD

Insulet Raises FY24 Revenue Growth To Range Of 20% - 21% (Previously 16% -19%)

Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. The company reported quarterly sales of $4.300 million which beat the analyst consensus estimate of $4.078 million by 5.44 percent. This is a 29.47 percent decrease over sales of $6.097 million the same period last year.

Senseonics Holdings Q3 2024 GAAP EPS $(0.04) Misses $(0.03) Estimate, Sales $4.300M Beat $4.078M Estimate

Expensify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXFY#NASDAQ">EXFY</a>) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is a 175 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $35.409 million which beat the analyst consensus estimate of $35.013 million by 1.13 percent. This is a 2.97 percent decrease over sales of $36.494 million the same period last year.

EXFY

Expensify Q3 2024 Adj. EPS $0.06, Inline, Sales $35.409M Beat $35.013M Estimate

Business Outlook
Five9 provides guidance based on current market conditions and expectations. Five9 emphasizes that the guidance is subject to various important cautionary factors referenced in the section entitled "Forward-Looking Statements" below, including risks and uncertainties associated with ongoing impact of macroeconomic challenges.
<ul>
<li>For the full year 2024, Five9 now expects to report:
<ul>
<li>Revenue in the range of $1.030 to $1.031 billion.</li>
<li>GAAP net loss per share in the range of $(0.30) to $(0.23), assuming basic shares outstanding of approximately 74.5 million.</li>
<li>Non-GAAP net income per share in the range of $2.36 to $2.38, assuming diluted shares outstanding of approximately 75.0 million.</li>
</ul>
</li>
<li>For the fourth quarter of 2024, Five9 expects to report:
<ul>
<li>Revenue in the range of $267.0 to $268.0 million.</li>
<li>GAAP net income per share in the range of $0.03 to $0.08, assuming diluted shares outstanding of approximately 88.6 million.</li>
<li>Non-GAAP net income per share in the range of $0.69 to $0.71, assuming diluted shares outstanding of approximately 76.0 million.</li>
</ul>
</li>
</ul>
With respect to Five9's guidance as provided above, please refer to the "Reconciliation of GAAP Net Loss to Non-GAAP net income - Guidance" table for more details, including important assumptions upon which such guidance is based.

FIVN

Five9 Sees Q4 EPS $0.69-$0.71 Vs $0.68 Est.; Revenue $267M-$268M Vs $261.15M Est.; FY24 EPS $2.36-$2.38 Vs $2.27 Est.; Revenue $1.03B-$1.031B $1.02B Vs Est.

Fresh Tracks Therapeutics GAAP EPS of $0.32, revenue of $7.94M

Fresh Tracks Therapeutics common stock to be suspended from trading on Nasdaq at open of business on Dec 19

Fresh Tracks Therapeutics to hold new stockholders meeting to seek liquidation approval

Fresh Tracks Therapeutics (FRTX) has released an update. Fresh Tracks Therapeutics, Inc. stockholders convened for a crucial vote on the company's ...

Fresh Tracks Therapeutics Shareholders Vote on Dissolution

The latest update is out from Fresh Tracks Therapeutics (FRTX). Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. mutually agreed to term...

Fresh Tracks Therapeutics Ends Deal with Carna Biosciences

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Fresh Tracks Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/frtx-stock-quote/">FRTX</a>) just reported results for the fourth quarter of 2023.<ul><li>Fresh Tracks Therapeutics reported earnings per share of -20 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/frtx-stock-earnings-fresh-tracks-therapeutics-for-q4-of-2023/">FRTX Stock Earnings: Fresh Tracks Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Comments

Fresh Tracks Therapeutics

Notizie

Ultime notizie per Fresh Tracks Therapeutics (OTC:FRTX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO